The Bayer stock price has seen extreme fluctuation recently following various impactful events. Consequences from the Roundup case in the U.S. court had a negative effect on Bayer stocks, with a significant plunge after the firm was ordered to pay $2B. The situation worsened as another verdict had Bayer paying $2.1B in Georgia, causing a 7% reduction in Bayer shares. As a result, the firm is considering a hefty capital raise. Market regulation scrutiny followed the dramatic drop in Bayer shares. However, the stocks managed to regain some lost ground due to reasonably optimistic growth view for FY26 despite a Q4 loss and a cautious FY25 outlook. Bayer's profitability has been hampered by sluggish farming prices but has forecast an improvement in 2026. The firm has also hooked up with the likes of Suzhou Puhe BioPharma, gaining rights for their PRMT5 inhibitor and OneMedNet for AI Medical Imaging Innovation. The completion of the acquisition of Camelina assets was also announced.
BAYER Stocks News Analytics from Tue, 06 Aug 2024 07:00:00 GMT to Fri, 28 Mar 2025 04:08:37 GMT - Rating -5 - Innovation -1 - Information 7 - Rumor 3